Skip to main content
OpenTrials
Completed

NCT Number: NCT05088486

The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population

This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Deputy head of Gerontology Center of Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan

Almaty, Kazakhstan

About this study

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons with confirmed arterial hypertension;
  • The age of patients is from 18 to 55 years old inclusive;
  • Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs;
  • Persons who are able and willing to provide written informed consent;
  • Persons capable and willing to comply with the research protocol;

Exclusion criteria

  • Persons under 18 and over 55;
  • Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  • Pregnant or lactating women;
  • Tuberculosis of any localization in the active phase and in history;
  • Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
  • Severe and decompensated course of endocrine diseases;
  • Autoimmune diseases;
  • Systemic diseases;
  • Cancer.

Treatment and study plan

DNA analysis

Genetic

GWAS

Primary outcomes

  1. number of SNPs associated with arterial hypertension

    Time frame: 1 year

    Using GWAS to identify candidate genes associate with arterial hypertension

Sponsors and collaborators

Lead sponsor

Asfendiyarov Kazakh National Medical University

Other

Registry information

Official study title

Preventive and Personalized Medicine (2021-2023)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 22, 2021
Registry last updated
Mar 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.